ImmunityBio (NASDAQ:IBRX) Issues Earnings Results

ImmunityBio (NASDAQ:IBRX - Get Free Report) posted its earnings results on Monday. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.03), Zacks reports.

ImmunityBio Stock Down 1.0%

ImmunityBio stock opened at $2.07 on Monday. The business's 50-day simple moving average is $2.68 and its 200 day simple moving average is $3.38. The stock has a market cap of $1.83 billion, a price-to-earnings ratio of -2.25 and a beta of 0.33. ImmunityBio has a 12-month low of $1.83 and a 12-month high of $9.16.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. HC Wainwright reaffirmed a "buy" rating on shares of ImmunityBio in a report on Monday, May 5th. D. Boral Capital restated a "buy" rating and set a $30.00 price objective on shares of ImmunityBio in a research report on Wednesday, April 23rd. One investment analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $12.19.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.